製品・受託サービス

ResidenceTimer™  Target List

ビオチン分子を一つだけラベリングしたキナーゼを用いることによりばらつきの無いセンサーチップへの固相化が可能となりました。
全ターゲットNTRC社で最適化された均一アッセイバッファーにて試験が行われる為ターゲット間のデータ比較が容易です。
Kinase Domain 対照化合物として評価可能薬剤
ABL (ABL1) full length ponatinib, bosutinib, dasatinib, imatinib
AKT1 catalytic domain pan-Akt inhibitor
AKT2 catalytic domain pan-Akt inhibitor
ALK cytoplasmic domain crizotinib
ALK[L1196M] cytoplasmic domain crizotinib
AurA (AURKA) full length pan-Aurora inhibitors
AurB (AURKB)* full length pan-Aurora inhibitor
AXL cytoplasmic domain crizotinib, sunitinib
BMX full length bosutinib, dasatinib
BRAF catalytic domain dabrafenib, vemurafenib
BTK* full length ponatinib, ibrutinib, dasatinib
BTK full length ponatinib, ibrutinib, dasatinib
CHK1 (CHEK1) full length bosutinib, sunitinib
CSF-1R/FMS cytoplasmic domain dasatinib
DDR2* cytoplasmic domain ponatinib, dasatinib, imatinib, sorafenib
EGFR cytoplasmic domain afatinib, erlotinib, gefitinib
EGFR[T790M/L858R] cytoplasmic domain osimertinib
FAK (PTK2) truncated human crizotinib
FGFR1* cytoplasmic domain ponatinib, sunitinib, pan-FGFR inhibitor
FGFR3* cytoplasmic domain sunitinib, pan-FGFR inhibitor
FGFR4 cytoplasmic domain sunitinib, pan-FGFR inhibitor
FLT3 cytoplasmic domain imatinib, dasatinib
FYN [isoform a] full length ponatinib, regorafenib
IGF1R* cytoplasmic domain staurosporine, cabozantinib, IGF-1R inhibitors
IKKα (CHUK) full length IKKβ inhibitor
IKKα (CHUK) [K44A] inactive full length IKKβ inhibitor
IRAK4 full length crizotinib, sunitinib
ITK* full length crizotinib, sunitinib
KDR (VEGFR2) cytoplasmic domain vandetanib
KIT* cytoplasmic domain pazopanib, masitinib, staurosporine
LCK full length ponatinib, regorafenib
LYNa full length ponatinib, regorafenib
MAP2K1 inactive full length crizotinib, dasatinib, MEK inhibitors
MAP3K5 catalytic domain staurosporine, bosutinib, sunitinib, pan-Akt inhibitor
MET cytoplasmic domain crizotinib
PAK4 full length staurosporine, bosutinib, pan-Akt inhibitor
p38α (MAPK14) truncated human sorafenib, p38 MAPK inhibitors
p38α (MAPK14) inactive truncated human sorafenib, p38 MAPK inhibitors
PIK3CA/PIK3R1 full length pictilisib, dactolisib
PIK3CB/PIK3R1 full length apitolisib
PIK3CD/PIK3R1 full length idelalisib, duvelisib
PIK3CG/PIK3R5 full length apitolisib, duvelisib
PKN1 full length pan-Akt inhibitor
PLK1 full length PIk1 inhibitor
PYK2 (PTK2B)* full length crizotinib
RET cytoplasmic domain ponatinib, regorafenib, vandetanib, dasatinib, sorafenib
ROCK1 catalytic domain ROCK inhibitors, multikinase inhibitor, angiokinase inhibitor
SRC full length ponatinib, regorafenib
SRPK1 full length staurosporine
SYK* full length staurosporine
TIE2* cytoplasmic domain ponatinib, vandetanib
TNIK catalytic domain bosutinib, sunitinib
TRKA (NTRK1)* cytoplasmic domain Trk inhibitor, ponatinib
TRKA (NTRK1) cytoplasmic domain Trk inhibitor, ponatinib
TRKB (NTRK2)* cytoplasmic domain Trk inhibitor, ponatinib
TRKB (NTRK2) cytoplasmic domain Trk inhibitor, ponatinib
TRKC (NTRK3)* catalytic domain sorafenib, Trk inhibitor
* ATP処理を施していない製品として「Non-Activated 」版も取り揃えております
Page Top